Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS
Komal Jhaveri, MD, FACP
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Charles Turck, PharmD, BCPS, BCCCP
Matthew Lunning, DO, FACP
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Aline Fares, MD
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Ryan Quigley
David F. McDermott, MD
Assessing Efficacy and Cost of Blood-Based Tests for Colorectal Cancer
Samuel Muench, MD
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
Brennan Spiegel, MD, MSHS
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
Richard Kim, MD
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Jorge Nieva, MD
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Wayne Kuang, MD
William Oh, MD
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.